| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| ln Vivo |
secoxyloganin (10 mg/kg, oral administration) significantly inhibited the decrease in blood flow (BF) in the tail vein of HEL-sensitized mice compared with the control group after day 6 or 7 of sensitization (p<0.05, Dunnett's test with Bonferroni). The BF decrease was monitored daily for 9 days. [1]
secoxyloganin (10 mg/kg, p.o.) showed no inhibition of platelet aggregation in whole blood induced by ADP (8 μM) when compared with the control group (data not shown). [1] |
|---|---|
| Animal Protocol |
In vivo allergy-preventive activity assay: Male ddY mice (5 weeks old) were sensitized intraperitoneally with 50 μg of hen-egg white lysozyme (HEL) in complete Freund’s adjuvant on day 0. secoxyloganin was dissolved in water and administered orally at a dose of 10 mg/kg (10 μL test solution per gram body weight) on days 0 (starting day), 3, 6, and 9 after sensitization. Blood flow in the tail vein was measured daily for 9 days using a laser Doppler blood flow meter of the contact type. Each mouse was pre-warmed for 10 min at 36°C before measurement and placed in a holding chamber kept at 36°C. Normal BF was measured for 10 min one day before the experiment, and BF of sensitized mice was measured for 10 min without anesthesia. Results were expressed as mean ± S.E. of the percentage of normal BF of each mouse. None of the reagents affected the BF. [1]
Platelet aggregation assay: On day 9 after sensitization, whole blood was collected from each anesthetized mouse (diethyl ether) and anticoagulated with 3.8% sodium citrate, then left to stand for 30 min at room temperature. Platelet aggregation induced by ADP (8 μM) was measured using a whole blood aggregometer (WBA) analyzer based on the screen filtration pressure (SFP) method. secoxyloganin was administered orally at 10 mg/kg on days 0, 3, 6, and 9. [1] |
| References | |
| Additional Infomation |
Secoxyloganin is a secoxyloganin glycoside with the chemical formula [(2R,3R,4S)-2-hydroxy-5-(methoxycarbonyl)-3-vinyl-3,4-dihydro-2H-pyran-4-yl]acetic acid, in which non-stoichiometric hydroxyl groups are converted to the corresponding β-D-glucoside. It has been isolated from various plants and possesses antioxidant and anti-allergic properties. It is a plant metabolite, antioxidant, and anti-allergen. It is a methyl ester, pyranoid, acrylate, β-D-glucoside, monosaccharide derivative, dicarboxylic acid monoester, and secoxyloganin glycoside. It is the conjugate acid of secoxyloganin (1-). Secoxyloganin has been reported in Calycophyllum spruceanum, Picconia excelsa, and other organisms with relevant data. See also: Honeysuckle (partial).
secoxyloganin is a secoiridoid glucoside. It was isolated from the water extract (H₂O ext.) of Lonicera japonica flower buds, with a yield of 0.037% (102 mg from 500 g dried plant material). Its structure was identified by comparison of physical and spectroscopic data (MS, UV, IR, ¹H- and ¹³C-NMR) with literature values. [1] The molecular weight of secoxyloganin is approximately similar to other tested iridoids (loganin, sveroside, chlorogenic acid etc.). The dose of 10 mg/kg corresponds to approximately 26 μmol/kg. [1] In the discussion, it is noted that secoiridoids (including secoxyloganin and loganin) have rarely been reported for anti-allergic activity; only one previous study reported an inhibitory effect on histamine release from rat mast cells (Yoshikawa et al., 1994). This reference is cited but not part of the current experimental data. [1] secoxyloganin did not inhibit platelet aggregation, suggesting that its mechanism of inhibiting BF decrease is different from that of flavanones and chalcones previously studied. Possible mechanisms mentioned for iridoid derivatives include inhibition of COX-2 production, NO production, or expression of iNOS and COX-2, but these were not specifically tested for secoxyloganin. [1] |
| Molecular Formula |
C17H24O11
|
|---|---|
| Molecular Weight |
404.3659
|
| Exact Mass |
404.131
|
| CAS # |
58822-47-2
|
| PubChem CID |
162868
|
| Appearance |
White to light yellow solid
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
649.5±55.0 °C at 760 mmHg
|
| Flash Point |
231.8±25.0 °C
|
| Vapour Pressure |
0.0±4.4 mmHg at 25°C
|
| Index of Refraction |
1.589
|
| LogP |
-2.02
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
28
|
| Complexity |
618
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@@]([H])([C@]([H])([C@]1([H])O[C@@]1([H])[C@]([H])(C([H])=C([H])[H])[C@]([H])(C([H])([H])C(=O)O[H])C(C(=O)OC([H])([H])[H])=C([H])O1)O[H])O[H])O[H]
|
| InChi Key |
MQLSOVRLZHTATK-PEYNGXJCSA-N
|
| InChi Code |
InChI=1S/C17H24O11/c1-3-7-8(4-11(19)20)9(15(24)25-2)6-26-16(7)28-17-14(23)13(22)12(21)10(5-18)27-17/h3,6-8,10,12-14,16-18,21-23H,1,4-5H2,2H3,(H,19,20)/t7-,8+,10-,12-,13+,14-,16+,17+/m1/s1
|
| Chemical Name |
2-[(2S,3R,4S)-3-ethenyl-5-methoxycarbonyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-4-yl]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~247.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4730 mL | 12.3649 mL | 24.7298 mL | |
| 5 mM | 0.4946 mL | 2.4730 mL | 4.9460 mL | |
| 10 mM | 0.2473 mL | 1.2365 mL | 2.4730 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
